MedPath
HSA Approval

CALCIUM FOLINATE INJECTION 10 mg/ml

SIN07916P

CALCIUM FOLINATE INJECTION 10 mg/ml

CALCIUM FOLINATE INJECTION 10 mg/ml

November 15, 1994

PFIZER PRIVATE LIMITED

PFIZER PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPFIZER PRIVATE LIMITED
Licence HolderPFIZER PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

INJECTION

**4.2. Posology and Method of Administration** Calcium folinate may be given parenterally by intramuscular injection, intravenous injection or intravenous infusion. When required for intravenous infusion, it may be diluted with 5% Glucose Injection or 0.9% Sodium Chloride Injection. Diluted solutions should be used immediately, but if this is not possible the diluted solution may be stored for a maximum of 24 hours at 2–8°C, protected from light. **Calcium Folinate Rescue (Adults and Children)** Calcium folinate may be used in conjunction with folic acid antagonists, e.g. Methotrexate, to reduce their systemic toxicity. It is given 12 to 24 hours after the antineoplastic drug. Doses of up to 120 mg maybe given over 12 to 24 hours by intramuscular injection or intravenous injection or infusion followed by 12 to 15 mg intramuscularly or 15 mg orally, every 6 hours for the next 48 hours. With lower doses of methotrexate, leucovorin 15 mg orally every 6 hours for 48 to 72 hours may be sufficient. **Treatment of Megaloblastic Anaemia** The dose should not exceed 1 mg daily given intramuscularly. When given orally, the recommended dosage is one Calcium Leucovorin Tablet (15 mg) daily. Children up to 12 years: 0.25 mg/kg/day. Normal adult dosage: 10–20 mg daily. **Treatment of Overdosage of Folic Acid Antagonists** In cases of overdosage of folic acid antagonists, calcium folinate may be administered by intravenous infusion in doses of up to 75 mg within 12 hours, followed by 12 mg intramuscularly every 6 hours for 4 doses. In general, where overdosage is suspected, the dose of calcium folinate should be equal to or greater than the offending dose of the folic acid antagonist administered, and should be given as soon as possible; preferably within the first hour and certainly within 4 hours after which it may not be effective.

INTRAVENOUS, INTRAMUSCULAR

Medical Information

**4.1. Therapeutic Indications** Calcium folinate is indicated in: 1. Neutralising the immediate toxic effects of folic acid antagonists, e.g. Methotrexate. 2. Calcium Folinate Rescue - a treatment technique using calcium folinate in conjunction with folic acid antagonists, e.g. methotrexate, to minimise systemic toxicity. 3. The treatment of megaloblastic anaemias due to sprue, nutritional deficiency, pregnancy, infancy, liver disease and malabsorption syndrome when oral therapy is not possible.

**4.3. Contraindications** - Known hypersensitivity to calcium folinate, or to any of the excipients. - Pernicious anaemia or other anaemias due to vitamin B12 deficiency. Regarding the use of calcium folinate with methotrexate or 5-fluorouracil during pregnancy and lactation, see section 4.6, “Pregnancy and Lactation” and the summaries of product characteristics for methotrexate- and 5-fluorouracil- containing medicinal products – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.

V03AF03

calcium folinate

Manufacturer Information

PFIZER PRIVATE LIMITED

Hospira Australia Pty Ltd

Active Ingredients

CALCIUM FOLINATE EQV FOLINIC ACID

10 mg/ml

Leucovorin

Documents

Package Inserts

Calcium folinate injection PI.pdf

Approved: October 21, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.